Introduction
Cancer therapy is hampered by dose-limiting side effects that reduce the efficacy of cancer treatments. Conventional drugs used for treatment do not selectively accumulate in the tumor (1) . Thus, important research goals include delivering high doses of drug to tumor sites for maximum treatment efficacy while minimizing side effects to healthy tissues (2) . In the search for more effective treatments, efforts are made to develop drugs that selectively target tumor antigens to preferentially deliver the therapeutic agent to the tumor site (1, 3) . Antigen heterogeneity among diverse types of tumors, and among tumor cells of the same tumor, renders this approach effective only in specific cases.
Other strategies target tumoral neovasculature. Angiogenesis is a hallmark feature of cancer growth and tumor vessels in distinct tumors may also express markers that are different from normal vasculature (4) . The targeting of angiogenesis is therefore applicable to a wide range of different tumors. Antibodies targeting VEGF, PDGF, and integrins have been described and used to alter tumor vessels in animal and clinical studies (5) (6) (7) (8) . Unfortunately, anti-angiogenic therapies in cancer have until now shown only limited or transient effects (9) (10) (11) .
Platelets are a rich source of pro-and anti-angiogenic factors that are released in the circulation upon platelet activation (12) . Platelets also maintain the integrity of angiogenic and inflamed microvessels (13, 14) . Furthermore, we recently showed that platelets support tumor vascular homeostasis by preventing intratumoral hemorrhaging 4 (15) . The tumor bleeding induced by thrombocytopenia cannot be prevented by degranulated platelets suggesting that the local release of soluble factors protects the tumor endothelium against injuries produced by tumor-associated inflammatory cells (15, 16) .
Because thrombocytopenia renders vessels in the tumor leaky, we hypothesized that this leakiness would enhance the access of chemotherapy to the tumor. Paclitaxel is a wellknown therapeutic drug used to treat breast cancer. It acts as a mitotic inhibitor that stabilizes microtubules, interfering with their normal breakdown during cell division inducing apoptosis (17) (18) (19) . Here we show that thrombocytopenia promotes the accumulation of inert particles at the tumor site reflecting an increase in porosity of the tumor vessels. Using mammary and lung carcinoma mouse models, we show that thrombocytopenia enhances the inhibitory effect of paclitaxel on tumor growth without increasing its toxicity to other organs.
Materials and Methods
Cell lines and reagents. The 4T1 and LLC cell lines were maintained in high glucose The 4T1 cell line was originally isolated from a spontaneously arising mammary tumor in a BALB/c mouse (20) whereas LLC cells originated from C57BL/6 mice. The 4T1
and LLC cells were injected in syngeneic mice after less than 4 and 10 serial passages in vitro respectively. For the fast-growing 4T1 model, the cells were cultivated for over 25 passages. All cell lines were obtained from and characterized by ATCC according to the cell line authentification testing (growth curve analysis, mycoplasma, bacteria, and fungi contamination, DNA profiling, species confirmation) and were used within 6 months after resuscitation. All cell culture products were purchased from Life Technologies/Invitrogen.
Animals. All animal procedures described in this study were performed using 6-to 8-wk-old BALB/c female mice or C57BL/6 males (purchased from The Jackson Laboratory) except in experiments using dorsal skinfold chamber for which 10-wk-old mice were used. All experimental procedures involving the use of mice were approved by the Animal Care and Use Committee of the Immune Disease Institute.
Induction of thrombocytopenia. Thrombocytopenia was induced by an i.v. injection of 2.5 μg/g of a platelet depleting antibody (polyclonal rat IgG anti-mouse GPIbα; emfret Analytics). Control mice were injected with a non-immune rat polyclonal IgG (emfret 6 Analytics). Thrombocytopenia was verified by flow cytometry and resulted in less than 5% of normal platelet count.
Determination of hemoglobin content. Organs and tumors of sacrificed animals were excised, weighed, homogenized in Drabkin's reagent (Sigma), and centrifuged (2000 x g; 10 min). Hemoglobin content of supernatants was measured by absorbance at 540 nm.
Immunohistology. Tumors and organs were harvested from sacrificed animals and fixed in zinc fixative (100 mmol/L Tris-HCl containing 37 mmol/L zinc chloride, 23 mmol/L zinc acetate, and 3.2 mmol/L calcium acetate). Paraffin-embedded sections were deparaffinized in xylenes and rehydrated through a graded alcohol series. For Perl's Prussian blue staining, the sections were transfered to a mixture of equal parts of 2% potassium ferrocyanide and 2% hydrochloric acid. Sections were counterstained with nuclear fast red. Tissues were dehydrated, mounted in DPX mountant (Fluka BioChemika) and observed by light microscopy. For quantification of apoptosis, the sections were permeabilised and stained with terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL; Roche Applied Science) according to the manufacturer's instructions. For quantification of proliferation, the sections were stained with Ki-67-Alexa 555 conjugated antibody (BD Biosciences). For quantification of apoptotic endothelial cells, the sections were stained with TUNEL as described above, incubated with a rat anti-CD31 antibody (eBioscience) and anti-rat Alexa-594 
Results
Acute thrombocytopenia induces bleeding only at the tumor site. We previously showed that thrombocytopenia induces tumor hemorrhage without any macroscopic signs of bleeding in other organs (15) . To address this more precisely, we determined the hemoglobin content, reflecting the level of red blood cell extravasation, of the major organs in thrombocytopenic versus control tumor-bearing mice. For this purpose, 4T1 mammary carcinoma cells were implanted in the mammary fat pad of BALB/c syngeneic mice and allowed to grow. At day 8, platelet depletion was induced for 24 hours; subsequently mice were sacrificed and the hemoglobin content of the organs and tumor was quantified. The hemoglobin content in the tumors of mice with normal platelet count was similar to that of the skin and less than that of highly vascularized organs such as lung, liver, and heart as expected (23) . No significant difference in the hemoglobin content of major organs was found between thrombocytopenic mice and controls ( Figure   1A ). In contrast, a significant increase in hemoglobin content and the presence of Cell counter analysis of blood samples collected three days after the mice received combined treatments revealed a persistent significant reduction in platelet count but no significant differences in the number of white blood cells and red blood cells compared to the other groups ( Figure 6 ). Although not significant, thrombocytopenic mice showed a tendency toward reduced number of red blood cells. This reduction could be explained by the tumor hemorrhage occurring in these mice. Altogether our results indicate that by depleting platelets and rendering leaky only the vessels of the tumor, we enhanced the access of chemotherapy to the tumor site specifically and did not increase its general toxicity.
Thrombocytopenia allows accumulation of microspheres and enhances the effect of paclitaxel on Lewis lung carcinoma (LLC) tumor growth.
We previously showed that thrombocytopenia-induced tumor hemorrhage was independent of the type, age, and localization of the tumor (15) . To examine whether increased drug delivery to tumors in thrombocytopenic mice could be generalized to other tumors, we studied LLC inoculated into the flank of syngeneic mice. First, we evaluated if thrombocytopenia-induced tumor hemorrhage in this model allows the accumulation of circulating particles at the tumor site. Indeed, fluorescently-labeled microspheres accumulated preferentially in the hemorrhagic compared to the non-hemorrhagic tumors ( Figure 7A) . Moreover, the combined treatment of platelet depletion and paclitaxel injection also resulted in a significant reduction of LLC tumor growth compared to treatment with paclitaxel alone.
( Figure 7B ). These results indicate that low platelet counts can be used to increase the (15, 16) . Given that all tumors are both angiogenic and pro-inflammatory (25, 26) , we now show that the thrombocytopenia-induced leakiness of tumor vessels allows better access of a chemotherapeutic agent to the tumor, thus increasing its efficacy.
An important goal in cancer therapy is to deliver high doses of drug to tumor sites while minimizing side effects to healthy organs. Conventional drugs used for cancer treatment are administered systemically and distribute within the different organs and tissues of the body. The dose that reaches the tumor mass may be as little as 5-10% of that which accumulates elsewhere (27) . Therapies that target specific tumor antigens are limited by their specificity and may not be possible to develop for cancers that are not well-defined. (28), inhibition of platelet function to improve drug delivery should be widely applicable.
Mouse models of disease treatment are not always directly applicable to human patients.
In fact, the use of thrombocytopenia to improve chemotherapeutic treatment could raise concerns for the well-being of patients. However, we showed here that no signs of systemic hemorrhage were associated with thrombocytopenia. Moreover, low platelet counts needed to be achieved only transiently to be effective in our model. We previously showed that commencement of tumor hemorrhage can be seen as soon as 30 minutes after the induction of thrombocytopenia (15) . Perhaps thrombocytopenia would only need to occur long enough to induce tumor hemorrhage and allow drug accumulation. It must also be noted that chemotherapeutic agents are characterized by a short half-life.
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